BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CPC Scientific - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://test.cpcscientific.com
X-WR-CALDESC:Events for CPC Scientific
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240327T100000
DTEND;TZID=America/Los_Angeles:20240327T110000
DTSTAMP:20260521T023453
CREATED:20240302T022613Z
LAST-MODIFIED:20240326T014343Z
UID:10000042-1711533600-1711537200@test.cpcscientific.com
SUMMARY:zED Event #3: Virtual Webinar
DESCRIPTION:CPC Scientific is proud to be speaking at the third Aralez Bio virtual zED event on March 27th! Join John Phipps (CPC Scientific Inc.) and Leendert van den Bos (EnzyTag BV) for virtual talks moderated by Michael Kopach (Eli Lilly and Company)! \n10:00-11:00 PDT | 13:00-14:00 EDT | 17:00-18:00 UTC Moderated by Dr. Michael Kopach\, Assoc. VP\, Eli Lilly Talks from Dr. Leendert van den Bos (EnzyTag) and John Phipps (CPC Scientific)\nRegister
URL:https://test.cpcscientific.com/event/zed-event-3-virtual-webinar/
LOCATION:Virtual Event\, United States
CATEGORIES:Exhibitions,Presentations,Webinars
ATTACH;FMTTYPE=image/png:https://test.cpcscientific.com/wp-content/uploads/2024/03/zEDevents_thumbnail_700px-min.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20211026T080000
DTEND;TZID=UTC:20211028T170000
DTSTAMP:20260521T023453
CREATED:20210927T230304Z
LAST-MODIFIED:20210927T231556Z
UID:10000009-1635235200-1635440400@test.cpcscientific.com
SUMMARY:6th Neoantigen Based Therapies Summit 2021
DESCRIPTION:Join the Neoantigen Based Therapies Summit to connect with the pioneers of the neoantigen field setting a trailblazing fire to the immunotherapy industry as they gather online to discuss what the optimal control\, clinical and combination trial designs should look like\, and explore how we can manufacture effectively and at scale both shared and personalized neoantigen based therapies.
URL:https://test.cpcscientific.com/event/6th-neoantigen-based-therapies-summit-2021/
LOCATION:Virtual Event\, United States
CATEGORIES:Exhibitions
ATTACH;FMTTYPE=image/jpeg:https://test.cpcscientific.com/wp-content/uploads/2021/09/2021-Neoantigen-wht-bk-sm-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210811T090000
DTEND;TZID=UTC:20210811T100000
DTSTAMP:20260521T023453
CREATED:20210722T031012Z
LAST-MODIFIED:20251104T060835Z
UID:10000008-1628672400-1628676000@test.cpcscientific.com
SUMMARY:25 years developing GLP-1 mimetics for diabetes and metabolic diseases – the future is still very bright.
DESCRIPTION:25 years developing GLP-1 mimetics for diabetes and metabolic diseases – the future is still very bright.Richard Pittner\, PhD\, VP of Discovery Biology\, Escient Pharmaceuticals Inc.GLP-1 was identified as the first incretin\, released post-prandially to stimulate a decrease in blood glucose levels. Unlike administered insulin or other oral agents\, GLP-1 does not cause hypoglycemia. Its insulin-releasing effect is glucose-dependent\, alongside its ability to delay post-prandial glucose excursion – making it a very attractive target for pharmaceutical development. Byetta (Exendin-4)\, the first potent and long-lasting GLP-1 mimetic\, paved the way for demonstrating the therapeutic value of GLP-1 agonism. Since Byetta’s approval in 2005\, a number of GLP-1 agonists are now available such as Liraglutide (Victoza) and Dulaglutide (Trulicity)\, with more favorable efficacy and delivery options. The differentiation requirement is now set very high for the next generation of therapeutics. This presentation will focus on the development of the latest GLP-1 mimetics and GLP-1/GIP dual agonists\, with unparalleled efficacy and ease of delivery.Complete to View Webinar VideoName*FirstLastEmail address*Company*Country*Please selectUnited StatesAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua And BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia And HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo\, The Democratic Republic Of TheCook IslandsCosta RicaCote D'IvoireCroatia (Local Name: Hrvatska)CubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrance\, MetropolitanFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard And Mc Donald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran (Islamic Republic Of)IraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKorea\, Democratic People's Republic OfKorea\, Republic OfKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacauMacedonia\, Former Yugoslav Republic OfMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia\, Federated States OfMoldova\, Republic OfMonacoMongoliaMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint Kitts And NevisSaint LuciaSaint Vincent And The GrenadinesSamoaSan MarinoSao Tome And PrincipeSaudi ArabiaSenegalSeychellesSierra LeoneSingaporeSlovakia (Slovak Republic)SloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia\, South Sandwich IslandsSpainSri LankaSt. HelenaSt. Pierre And MiquelonSudanSurinameSvalbard And Jan Mayen IslandsSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania\, United Republic OfThailandTogoTokelauTongaTrinidad And TobagoTunisiaTurkeyTurkmenistanTurks And Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands (British)Virgin Islands (U.S.)Wallis And Futuna IslandsWestern SaharaYemenYugoslaviaZambiaZimbabweState*Please selectAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict Of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingState or Province*Website URL*DOWNLOADI agree to receive communications from CPC Scientific.CPC Scientific is committed to protecting and respecting your privacy\, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time\, we would like to contact you about our products and services\, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose\, please tick below to say how you would like us to contact you.
URL:https://test.cpcscientific.com/event/25-years-developing-glp-1-mimetics-for-diabetes-and-metabolic-diseases-the-future-is-still-very-bright/
LOCATION:Virtual Event\, United States
CATEGORIES:Webinars
ATTACH;FMTTYPE=image/jpeg:https://test.cpcscientific.com/wp-content/uploads/2021/07/R-Pittner-photo-300x300sm.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210511T090000
DTEND;TZID=UTC:20210511T220000
DTSTAMP:20260521T023453
CREATED:20210630T084138Z
LAST-MODIFIED:20211008T061726Z
UID:10000005-1620723600-1620770400@test.cpcscientific.com
SUMMARY:An emerging new class of pharmaceutical products: Proteins and peptides made entirely of D-amino acids.
DESCRIPTION:Speaker: \nDate: \nTime: \nDana Ault-Riche\, PhD\, Co-Founder and CSO\, Reflexion Pharmaceuticals\, Inc.\nMay 11\, 2021\n9:00am PST (5:00pm GMT-London\, 6:00pm CET-France\, and 12:00am-China)\n\n\n\nProteins and peptides that are made entirely of D-amino acids are resistant to proteolytic metabolism\, resulting in longer half-lives and markedly reduced immunogenicity. These inherent properties make D-proteins and D-peptides near ideal molecules for pharmaceutical products. Several drugs contain D-amino acids with Parsabiv (etelcalcetide)\, a 7 D-amino acid peptide disulfide linked to L-cysteine\, having the greatest D-amino acid content so far among marketed products. The technology of mirror image phage display combined with advances in chemical protein synthesis have enabled the systematic discovery and development of D-proteins with potencies that rival the activities of antibodies. This talk will highlight the technology behind this emerging field with examples of D-products currently in the pipeline. \nBiography \nDr. Ault-Riché has started 6 different biotechnology companies. Reflexion Pharmaceuticals is the leader in the development of D-proteins\, an innovative new class of pharmaceutical products. Hangzhou Ditai Pharmaceuticals is developing D-protein therapeutics for Asian markets. Zyomyx was the first protein microarray company and pioneered the development of nanostructured devices with specialized surfaces for protein attachment and testing. Pointilliste pioneered the development of high-content protein microarrays that could be interrogated by living cells. Diazyme is a global company that develops a wide range of new clinical diagnostic tests. AllChemie focused on the development of novel peptidomimetic medicines for the treatment of diabetes. Dr. Ault-Riché received a PhD from the University of Kansas and completed postdoctoral training at Stanford University with Nobel laureate Arthur Kornberg.
URL:https://test.cpcscientific.com/event/an-emerging-new-class-of-pharmaceutical-products-proteins-and-peptides-made-entirely-of-d-amino-acids/
LOCATION:Virtual Event\, United States
CATEGORIES:Webinars
ATTACH;FMTTYPE=image/jpeg:https://test.cpcscientific.com/wp-content/uploads/2021/05/Dana-image.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20201110T090000
DTEND;TZID=UTC:20201110T100000
DTSTAMP:20260521T023453
CREATED:20210630T064518Z
LAST-MODIFIED:20211115T123712Z
UID:10000004-1604998800-1605002400@test.cpcscientific.com
SUMMARY:USP’s Recommendations for Quality Attributes of Synthetic Peptide Drug Substances
DESCRIPTION:Speaker: Michael Verlander\, D.Phil.\, Proactive Quality Compliance\nDate: November 10\, 2020\nTime: 9:00am PST (17:00pm GMT-London\, 18:00pm CET-France\, and 1:00am-China) \n\nAbstract\nSince synthetic peptides are specifically excluded from many regulatory guidance documents – in particular\, those relating to specifications for drug substances and drug products – the development of appropriate specifications for regulatory filings can present significant challenges during peptide drug development. Because of this\, the United States Pharmacopeia (USP) has recently proposed a new monograph – <1503> Quality Attributes of Synthetic Peptide Drug Substances – which discusses potential quality attributes and associated test methods to be considered for inclusion in specifications for peptide drug substances. The presentation will review the recommendations provided in the new monograph in the context of existing regulatory guidance\, with particular focus on peptide-related impurities\, their identification and the development of methods for their quantification. \nBiography\nDr. Verlander is currently acting as an independent consultant supporting the pharmaceutical industry in the areas of product development and quality and regulatory compliance; he also serves as a member of USP’s Biologics Monographs-1 Peptides and Oligonucleotides Expert Committee\, as well as their Glatiramer Acetate Expert Panel. Prior to this\, he gained extensive experience in the areas of quality assurance and regulatory affairs in contract manufacturing organizations specializing in peptide APIs\, including: the PolyPeptide Group [as President of PolyPeptide Laboratories San Diego (2009-2013)\, Global Director of Quality Assurance and Regulatory Affairs (2003-2009)\, and Executive Vice President\, Quality Assurance and Regulatory Affairs and Co-founder\, PolyPeptide Laboratories\, Inc. (1996-2009)]; and Bachem California [as Vice President\, Technical and Regulatory Affairs (1986-1996)]. He has also worked in the area of peptide research and development [as Director of Peptide Research and Peptide Production\, Immunetech Pharmaceuticals (1985-1986); Research Director\, BioResearch\, Inc. (1978-1985); and as a member of the research faculty at the University of California\, San Diego\, Department of Chemistry (1972-1978)].\nDr. Verlander received his undergraduate and graduate training in organic chemistry at the University of Oxford and his postdoctoral training at the Salk Institute for Biological Studies\, La Jolla\, California. He has authored more than 50 peer-reviewed scientific papers and numerous patents on peptides and related topics.
URL:https://test.cpcscientific.com/event/usps-recommendations-for-quality-attributes-of-synthetic-peptide-drug-substances/
LOCATION:Virtual Event\, United States
CATEGORIES:Webinars
ATTACH;FMTTYPE=image/jpeg:https://test.cpcscientific.com/wp-content/uploads/2021/06/Michael-Verlander-v2-300x300sm.jpg
END:VEVENT
END:VCALENDAR